The Labs Your Doctor Didn't Run (Pre-Protocol Bloodwork Blueprint)

Most men who go to their doctor with low energy, poor sleep, declining strength, or low libido walk out with a single number and a reassurance that they are fine. That number is total testosterone, and while it is not meaningless, it is so incomplete that it can point you in entirely the wrong direction.

To understand why, you need to see the full system first.

Testosterone is made primarily in the testes, but the testes do not act on their own. They receive a signal from the brain, specifically from the pituitary gland, which releases something called luteinizing hormone, or LH, which is the chemical messenger that tells the testes to produce testosterone. Above the pituitary sits the hypothalamus, which controls how much LH gets released by sending its own signal called GnRH. So the chain runs from brain to pituitary to testes, and a problem at any point in that chain produces low testosterone, but the cause and the treatment are completely different depending on where the chain breaks.

That is the map. Now the markers make sense.

LH and FSH are what tell you where the problem is. If testosterone is low and LH is also low, the brain is not sending the signal and that is called central or secondary hypogonadism. If testosterone is low but LH is high, the brain is screaming but the testes are not responding, and that is primary hypogonadism. Without measuring both, you are treating a symptom while blind to the source. The Endocrine Society guideline from Bhasin et al. in 2018 makes this distinction explicit because the treatment path changes entirely based on which pattern you find.

Now, even if total testosterone looks acceptable, that number may not tell you how much testosterone is actually available to your cells.

Most testosterone in the blood is bound to proteins, and the one that matters most here is something called SHBG, which stands for sex hormone binding globulin, and what it does is hold testosterone in a form that your cells cannot use. Only the portion of testosterone that is unbound, called free testosterone, can actually enter a cell and produce an effect. The harmonized reference data from Travison et al. using 9,054 men set a total testosterone range of 264 to 916 nanograms per deciliter, but two men can sit at the same point in that range and have completely different amounts of free testosterone depending on their SHBG level. A man at 600 nanograms per deciliter with high SHBG can have less biologically active testosterone than a man at 400 nanograms per deciliter with low SHBG. That is the reason SHBG has to be measured and not assumed.

Estradiol belongs on this panel too, and not just as an afterthought. Testosterone converts to estradiol through a process called aromatization, and estradiol in men plays a role in bone density, cardiovascular health, and cognitive function. The problem is that standard estradiol assays are designed for female hormone ranges and are not sensitive enough at the lower concentrations found in men. Rosner et al. in 2013 made the case that accurate estradiol measurement in men requires a method called LC-MS/MS, which is liquid chromatography tandem mass spectrometry, a more precise testing method that can detect the smaller concentrations relevant to male physiology. Running the wrong assay gives you a number that looks precise but is not reliable.

Prolactin, DHEA-sulfate, progesterone, and cortisol round out the hormonal picture because each one can independently suppress the axis or explain symptoms that testosterone alone would never account for.

Metabolic markers come next, and the gap between what most panels test and what actually predicts problems is significant here.

A standard glucose test can come back perfectly normal while insulin resistance is already developing. This is because insulin resistance, which is a condition where cells stop responding efficiently to insulin so the pancreas has to produce more and more to keep blood sugar stable, shows up in elevated fasting insulin long before blood sugar climbs. By the time hemoglobin A1c, which reflects average blood sugar over roughly three months, starts to rise, the metabolic dysfunction has usually been present for years. Measuring fasting insulin alongside glucose gives you a picture of the system under load, not just the outcome of that load.

Cardiovascular markers follow the same logic of measuring the mechanism, not just the result.

A standard lipid panel gives you total cholesterol, LDL, HDL, and triglycerides. Those numbers are useful but incomplete. What actually drives atherosclerotic plaque buildup is not cholesterol concentration alone but the number of particles carrying it, and that is what something called apolipoprotein B measures. ApoB is the structural protein on LDL and related particles, so one ApoB molecule equals one atherogenic particle, which makes it a more direct count of cardiovascular risk than LDL cholesterol alone. High-sensitivity C-reactive protein, or hs-CRP, adds another layer by measuring active systemic inflammation, which is an independent predictor of cardiovascular events beyond what lipids show.

This matters at baseline because testosterone therapy affects red blood cell production.

Testosterone stimulates the kidneys to produce more erythropoietin, which is the hormone that drives red blood cell production, and this raises hematocrit, which is the percentage of blood volume made up of red blood cells. Higher hematocrit increases blood viscosity. The data from Ory et al. in 2022 found that men on testosterone therapy with hematocrit at or above 52 percent had a 35 percent higher risk of major cardiovascular events and venous thromboembolism compared to men below that threshold. A baseline hematocrit measurement before starting means you can track that number and respond to it before it becomes a problem.

IGF-1, which is insulin-like growth factor 1 and is the primary downstream marker of growth hormone activity, serves a similar purpose. It is not that the baseline number tells you whether to start a protocol. It is that without a baseline, you cannot measure whether what you are doing is working or whether it has pushed you outside a safe range.

The thyroid panel with TSH, free T3, and free T4 matters because thyroid dysfunction produces symptoms that overlap almost completely with low testosterone, and treating testosterone without knowing thyroid status means you may be solving for the wrong variable.

Most doctors run a fraction of this. Not because they are negligent, but because standard of care is built around population thresholds and single-visit billing codes, not around building a mechanistic picture of an individual. A number with no context tells you where you are but not why you are there. The point of a complete pre-protocol panel is not to collect data. It is to understand the system well enough that the intervention you choose actually matches the problem you have.

---

References

1. Bhasin S et al. Testosterone Therapy in Men With Hypogonadism. JCEM. 2018 — Endocrine Society guideline: diagnosis requires two fasting morning total T measurements, distinguish primary vs secondary via LH/FSH
2. Mulhall JP et al. Evaluation and Management of Testosterone Deficiency. AUA Guideline. J Urology. 2018 — Total T below 300 ng/dL threshold, recommend LH in all men with low T
3. Travison TG et al. Harmonized Reference Ranges for Circulating Testosterone Levels. JCEM. 2017 — 9,054 men, harmonized range 264-916 ng/dL
4. Ory J et al. Secondary Polycythemia in Men Receiving Testosterone Therapy. J Urology. 2022 — Hematocrit >=52% on TRT = 35% higher MACE/VTE risk (OR 1.35)
5. Rosner W et al. Toward Excellence in Testosterone Testing. JCEM. 2013 — Sensitive LC-MS/MS required for accurate male estradiol

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness